Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

CCCC US Equity

C4 Therapeutics, Inc.Health Care · Biological Products, (No Diagnostic Substances) · CIK 1662579 · FY ends Dec 31
$4.21
+0.03 (+0.72%)
USD · as of 2026-08-19 · marketstack
1 8-K filing · 0 13D · 5 13G
DateEventWhat happened / filerSource
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by RA CAPITAL MANAGEMENT, L.P.sec.gov ↗
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Lynx1 Capital Management LPsec.gov ↗
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Squadron Capital Management LLCsec.gov ↗
2026-08-1213G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by MORGAN STANLEYsec.gov ↗
2026-08-118-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-07-2713GSchedule 13G filed — ≥5% beneficial owner (passive) · by BlackRock, Inc.sec.gov ↗
Source: SEC EDGAR (public domain) · history starts 2026-07-27

Every row is a filed document, checked against its EDGAR index.